Qinlock

Chemical Nameripretinib
Dosage FormTablet (oral; 50 mg)
Drug ClassKinase inhibitors
SystemMultiple
CompanyDeciphera Pharmaceuticals
Approval Year2020

Indication

  • For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Document TitleYearSource
Qinlock (ripretinib) Prescribing Information.2021Deciphera Pharmaceuticals, Waltham, MA
Drug updated on 7/4/2023

More on this drug: Clinical Trials